{"entity":{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of IN10018 in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.","summary":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT05551507 by InxMed (Shanghai) Co., Ltd., with 150 participants planned, started 2020-07-27 and due to reach its primary completion in 2026-05-31. Interventions recorded: IN10018 in combination with PLD. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05551507","url":"https://clinicaltrials.gov/study/NCT05551507"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["in10018"],"companies":["inxmed-shanghai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05551507","phase":"1/2","setting":"A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018 in Combination With Standard Chemotherapy in Subjects With High-grade Serous Epithelial Ovarian Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","enrolled":150,"outcomes":[]},"route":"/trials/nct05551507/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"company":[{"id":"inxmed-shanghai","kind":"company","name":"InxMed (Shanghai)","route":"/companies/inxmed-shanghai/"}]}}